Richard Kender
Director/Board Member at BICYCLE THERAPEUTICS PLC
Net worth: 451 105 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Eric Shaff | M | 48 | 10 years | |
Pierre Legault | M | 63 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 5 years |
Kevin Lee | M | 55 |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009.
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | 9 years |
Janice Bourque | F | 67 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 8 years |
Mohammed Khoso Baluch | M | 66 | 12 years | |
Marcus Chapman | M | 53 | 9 years | |
Veronica Jordan | M | 73 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 5 years |
Alistair Milnes | M | 50 | 3 years | |
Mohamed Wa’el Ahmed Hashad | M | 61 | 3 years | |
Pascale Fouqueray-Grellier | M | 61 | 15 years | |
Sebastien Bolze | M | - | 15 years | |
Stephen Berenson | M | 63 | 5 years | |
Thomas Kuhn | M | 50 | 15 years | |
Kate Bingham | F | 58 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | 8 years |
Gregory Winter | M | 73 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | 15 years |
Joshua Hare | M | 61 | 10 years | |
Michael Skynner | M | 55 |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 8 years |
Matthew Henn | M | 49 | 12 years | |
Chirfi Guindo | M | 58 | 13 years | |
Neil Hare | M | 54 | 9 years | |
Jennifer Russo Wortman | F | - | 9 years | |
David Ege | M | 50 | 21 years | |
Dalton Smart | M | 58 | 15 years | |
Stephen Sands | M | 67 | - | |
Paul Lehr | M | 56 | 8 years | |
Travis Thompson | M | - | 6 years | |
Ursula Ungaro | F | 73 | 3 years | |
Carlo Tanzi | M | - | 9 years | |
Tom Glocer | M | 63 | 17 years | |
Willard Dere | M | 70 | 7 years | |
Caroline Litchfield | F | 55 | 34 years | |
Patricia Russo | F | 71 | 29 years | |
Peter Wendell | M | 73 | 21 years | |
Dennis Ausiello | M | 78 | 9 years | |
Thomas DesRosier | M | 69 | 8 years | |
Jose-Carlos Gutiérrez-Ramos | M | 61 | 3 years | |
Nancy Thornberry | F | 67 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 20 years |
Kurt Graves | M | 56 | 9 years | |
Claire Fraser-Liggett | M | 68 | 1 years | |
Lisa Locklear | F | 64 | 1 years | |
Pascale Boissel | F | 57 | 9 years | |
Sophie Hallakou-Bozec | M | - | 15 years | |
Paul Biondi | M | 54 | 4 years | |
Douglas Losordo | M | 65 | 3 years | |
Gary O'Neill | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 11 years |
Quentin Durand | M | - | 5 years | |
Teresa Young | M | 57 | 4 years | |
Kate Bingham | F | - |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | - |
Sanat Chattopadhyay | M | - | 15 years | |
Sylvie Bertrand | F | - | 3 years | |
Naveed Iqbal Siddiqi | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 3 years |
Gregory Fu | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | - |
Allan Gabor | M | - | 11 years | |
Chan Beals | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 8 years |
Nataliya Agafonova | M | 55 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert P. Luciano | M | - | 23 years | |
Richard Kogan | M | 81 | 21 years | |
Kenneth Frazier | M | 69 | 30 years | |
P. Vagelos | M | 94 | 19 years | |
Roger Pomerantz | M | 67 | 9 years | |
Fred Hassan | M | 78 | 6 years | |
John G. Aunins | M | 63 | 31 years | |
David Berry | M | 47 | 5 years | |
Lee Kalowski | M | 43 | 6 years | |
Richard Clark | M | 77 | 6 years | |
James Corbett | M | 65 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 4 years |
Robert Palmisano | M | 79 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 2 years |
Noubar Afeyan | M | 60 | 10 years | |
Myrtle Potter | F | 65 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support.
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA. | 18 years |
Raymond Gilmartin | M | 82 | 2 years | |
David Arkowitz | M | 62 | 7 years | |
David Norton | M | 72 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 2 years |
Kumi Sato | F | - | 6 years | |
Grégory Behar | M | 55 | 9 years | |
Lorence Kim | M | 49 | 6 years | |
Carlos Eduardo Represas de Almeida | M | 78 | - | |
Leslie Brun | M | 72 | 13 years | |
Thomas C. Südhof | M | 68 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 1 years |
Meryl Zausner | F | 67 | 5 years | |
Ismail Kola | M | 67 | 4 years | |
Craig Thompson | M | 71 | 10 years | |
Eric-Paul Pâques | M | 70 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Deborah Harland | M | 64 | 10 years | |
Caroline Dorsa | F | 64 | 22 years | |
Kenneth Bartizal | M | 72 | 20 years | |
Jason Rhodes | M | 54 | 4 years | |
Steven Goldstone | M | 78 | 6 years | |
Marino Carol | F | - | 8 years | |
Peter Wilkinson | M | 53 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 3 years |
William N. Kelley | M | 84 | - | |
Thomas Robert Cech | M | 76 | - | |
Werner Cautreels | M | 71 | 3 years | |
Anne Tatlock | F | 84 | - | |
Thomas Shenk | M | 77 | 11 years | |
Donald S. Brooks | M | 88 | - | |
David Anstice | M | 75 | 5 years | |
Peter Hutt | M | 89 | 4 years | |
John J Horan | M | - | 6 years | |
Charles Kidder | M | 79 | 12 years | |
Carolyn Ng | M | 40 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 81 | 81.00% |
United Kingdom | 16 | 16.00% |
France | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Kender
- Personal Network